Targeting MDM subsets (e.g., colony stimulating factor 1 R [CSF1R] inhibition and metabolic reprogramming) combined with immune checkpoint blockade or adoptive therapies represents a transformative strategy to overcome GBM immunotherapy resistance. This evidence concerns the gene CSF1R and glioblastoma.